Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07361692
Recruiting Not applicable

Effectiveness of Transcranial Direct Current Stimulation (tDCS) in the Management of Complex Regional Pain Syndrome

NCT07361692 · tracked via the Priya Life Science France tracker
Sponsor
Polyclinique de l'Europe
Phase
Not applicable
Started
2026-04-01
Last updated
2026-06-18

Condition(s) studied

Complex Regional Pain Syndrome (CRPS)

Investigational drug(s) / intervention(s)

transcranial direct current stimulationPlacebo

transcranial direct current stimulation: progressive increase in stimulation intensity up to 2 mA, then continuation at a plateau for a total of 20 minutes, then a decrease in stimulation intensity for 30 seconds at the end of the session before an automatic stop.

Placebo: The stimulation intensity is gradually increased up to 2 mA for 1 minute, then decreased to zero stimulation. A further increase in stimulation is programmed 10 minutes after the start of stimulation.

Study summary

Transcranial direct current stimulation (tDCS) is a non-invasive therapy increasingly used in facilities treating patients with chronic pain. This complementary therapy has the advantage of being non-pharmacological, with transient and mild side effects, an excellent safety profile, and good efficacy in the contexts where it has been the subject of dedicated research: neuropathic pain, fibromyalgia, and visceral pain. Few studies have focused on the application of tDCS in the context of complex regional pain syndrome (CRPS), which is a common condition.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Major * Clinically active or active complex regional pain syndrome (CRPS) with positive Budapest criteria * Scintigraphy showing signs consistent with CRPS * Being affiliated with or a beneficiary of a social security scheme Exclusion Criteria: * Algodystrophy no longer meeting the Budapest criteria * Relative contraindication to tDCS: psychosis (including treated psychosis), uncontrolled epilepsy, large scalp scar, intracerebral/intracranial metallic body * Pregnant or breastfeeding women * Minors * Persons under legal protection (guardianship, conservatorship, and protective supervision) * Persons deprived of their liberty by judicial or administrative order * Unwilling individuals who cannot give their consent or cannot return for scheduled visits according to the protocol

Primary outcome measure(s)

  • Analog Visual Scale — one month post treatment

Trial sites (1)

FacilityCityRegionStatus
Polyclinique de l'Europe Saint-Nazaire France Recruiting

More Polyclinique de l'Europe trials in France

Mesotherapy Treatment of Irritable Bowel Syndrome Active, not recruiting

Other trials for the same condition

Peripersonal Space Representation in Upper Limb Segmental Exclusion Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07361692 on ClinicalTrials.gov ↗ ← All trials in France